NasdaqCM - Delayed Quote USD

Aytu BioPharma, Inc. (AYTU)

Compare
2.2899 +0.0299 (+1.32%)
At close: 4:00 PM EDT
2.3600 +0.07 (+3.06%)
After hours: 5:58 PM EDT
Loading Chart for AYTU
DELL
  • Previous Close 2.2600
  • Open 2.2700
  • Bid --
  • Ask --
  • Day's Range 2.2500 - 2.3820
  • 52 Week Range 2.1100 - 3.5000
  • Volume 19,200
  • Avg. Volume 21,681
  • Market Cap (intraday) 14.081M
  • Beta (5Y Monthly) -1.43
  • PE Ratio (TTM) --
  • EPS (TTM) -2.8600
  • Earnings Date Nov 12, 2024 - Nov 18, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

aytubio.com

102

Full Time Employees

June 30

Fiscal Year Ends

Recent News: AYTU

View More

Performance Overview: AYTU

Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AYTU
19.37%
S&P 500
21.92%

1-Year Return

AYTU
23.41%
S&P 500
34.37%

3-Year Return

AYTU
95.71%
S&P 500
31.03%

5-Year Return

AYTU
99.05%
S&P 500
96.05%

Compare To: AYTU

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AYTU

View More

Valuation Measures

Annual
As of 10/14/2024
  • Market Cap

    13.90M

  • Enterprise Value

    9.02M

  • Trailing P/E

    --

  • Forward P/E

    9.82

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.15

  • Price/Book (mrq)

    0.50

  • Enterprise Value/Revenue

    0.11

  • Enterprise Value/EBITDA

    1.14

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -19.56%

  • Return on Assets (ttm)

    -1.06%

  • Return on Equity (ttm)

    -47.24%

  • Revenue (ttm)

    81M

  • Net Income Avi to Common (ttm)

    -15.84M

  • Diluted EPS (ttm)

    -2.8600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    20.01M

  • Total Debt/Equity (mrq)

    59.24%

  • Levered Free Cash Flow (ttm)

    4.81M

Research Analysis: AYTU

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 17.98M
Earnings -4.62M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Company Insights: AYTU

People Also Watch